NDAIM-IVSOLUTION
Approved
Jun 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ROBAXIN (methocarbamol) by Hikma. Approved for muscle relaxant [epc]. First approved in 1959.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROBAXIN (methocarbamol) is a centrally acting muscle relaxant administered via intramuscular or intravenous injection as a solution. It is indicated for acute musculoskeletal conditions and works through central nervous system depression to reduce muscle spasm. The drug has been a standard-of-care option since its 1959 approval.
LOE Approaching
LOE approaching with moderate competitive pressure (30 percentile rank) suggests a contracting brand with likely downsizing of commercial support and marketing teams.
Mechanism of Action
Pharmacologic Class:
Muscle Relaxant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ROBAXIN offers limited career growth given the LOE-approaching lifecycle and zero linked job postings. Roles on this brand typically focus on defending market share against generics and optimizing acute-care channel relationships rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on ROBAXIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.